Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 4, 2013, Pages 289-295

  Ballestri, Stefano ^a   Meschiari, Erica ^a   Baldelli, Enrica ^a   Musumeci, Francesca E ^a   Romagnoli, Dante ^a   Trenti, Tommaso ^b   Zennaro, Romeo G ^b   Lonardo, Amedeo ^a   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AUSL Modena   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FETUIN A;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SPLEEN; SUBCUTANEOUS FAT;

AGED; AGED, 80 AND OVER; ALPHA-2-HS-GLYCOPROTEIN; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SUBCUTANEOUS FAT;

EID: 84880448050     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0149     Document Type: Article

References (37)

1. Loria P, Adinolfi LE, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42:272-282.
2. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42: 320-330.
3. Maurantonio M, Ballestri S, Odoardi MR, et al. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: A novel approach to reduce cardiovascular risk? Arch Med Res 2011;42:337-353.
4. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-1350.
5. Musso G, Gambino R, Cassader M, et al. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-649.
6. Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: Intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) 2008;115:1-12.
7. Lonardo A, Bellentani S, Ratziu V, et al. Insulin resistance in non-alcoholic steatohepatitis: Necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011;5:279-289.
8. Mori K, Emoto M, Inaba M. Fetuin-A and the cardiovascular system. Adv Clin Chem 2012;56:175-195.
9. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767.
10. Yilmaz Y, Yonal O, Kurt R, et al. Serum fetuin A/a2HSglycoprotein levels in patients with non-alcoholic fatty liver disease: Relation with liver fibrosis. Ann Clin Biochem 2010; 47:549-553.
11. Lim P, Collet JP, Moutereau S, et al. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem 2007;53:1835-1840.
12. Bilgir O, Kebapcilar L, Bilgir F, et al. Decreased serum fetuin- A levels are associated with coronary artery diseases. Intern Med 2010;49:1281-1285.
13. Mori K, Ikari Y, Jono S, et al. Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis 2010;21:281-285.
14. Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008;118:2555-2562.
15. Voros K, Gráf L Jr, Prohászka Z, et al. Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur J Clin Invest 2011;41:703-709.
16. Dogru T, Genc H, Tapan S, et al. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2012;Jun 7. doi:10.1111/j.1365-2265.2012.04460.x.
17. Leaman DM, Brower RW, Meester GT, et al. Coronary artery atherosclerosis: Severity of the disease, severity of angina pectoris and compromised left ventricular function. Circulation 1981;63: 285-289.
18. Acikel M, Sunay S, Koplay M, et al. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg 2009;9:273-279.
19. Assy N, Djibre A, Farah R, et al. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254:393-400.
20. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606-607.
21. Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012;32:1242-1252.
22. Pontiroli AE, Pizzocri P, Giacomelli M, et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: Comparison with computerized tomography and with anthropometric measurements. Obes Surg 2002;12:648-651.
23. Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
25. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: Clinical practice recommendations. Diabetes Care 2002;25:S1-S147.
26. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for theManagement of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3121.
28. Ballestri S, Lonardo A, Nascimbeni F, et al. Non-alcoholic fatty liver disease (NAFLD): A novel cardiovascular risk factor. Intern Emerg Med 2012;7:S33-S46.
29. Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: An alarm for the heart? Liver Int 2007;27:891-894.
30. Wong VW, Wong GL, Yip GW et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011;60:1721-1727.
31. Haukeland JW, Dahl TB, Yndestad A, et al. Fetuin A in nonalcoholic fatty liver disease: In vivo and in vitro studies. Eur J Endocrinol 2012;166:503-510.
32. Wang H, Sama AE. Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med 2012;12:625-633.
33. Afsar CU, Uzun H, Yurdakul S, et al. Association of serum fetuin-A levels with heart valve calcification and other biomarkers of inflammation among persons with acute coronary syndrome. Clin Invest Med 2012;35:E206-E215.
34. Minas M, Mystridou P, Georgoulias P, et al. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD 2013;10:28-34.
35. Heinrichsdorff J, Olefsky JM. Fetuin-A: The missing link in lipid-induced inflammation. Nat Med 2012;18:1182-1183.
36. Lee YH, Lee SH, Jung ES, et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin- 2 and MCP-1. Atherosclerosis 2010;213:592-597.
37. Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012;56:605-613.